Press release
Two potent novel antiviral drugs for SARS-CoV-2
antiviral drugs
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72617
Market Overview
The global antiviral drugs market was valued at USD 61.2 billion in 2024 and is projected to reach USD 97.5 billion by 2034, growing at a CAGR of 4.8% during the forecast period.
Key Highlights:
• Market Size 2024: USD 61.2 billion
• Forecast 2034: USD 97.5 billion
• CAGR (2024-2034): 4.8%
• Primary Drivers: Rising prevalence of chronic viral infections (HIV, hepatitis), demand for pandemic preparedness, and increased R&D investments in targeted therapies.
• Challenges: High drug development costs, emergence of drug-resistant viral strains, and limited accessibility in developing economies.
• Leading Players: Gilead Sciences, GlaxoSmithKline (GSK), Merck & Co., Roche, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, and Cipla.
The market is evolving with a strong focus on personalized medicine, host-targeted antivirals, and broad-spectrum drugs, positioning it as a cornerstone of global healthcare resilience.
Segmentation Analysis
By Drug Class:
• Protease inhibitors
• Reverse transcriptase inhibitors
• Polymerase inhibitors
• Integrase inhibitors
• Fusion inhibitors
• Others (entry inhibitors, monoclonal antibodies)
By Application:
• HIV/AIDS
• Hepatitis (B & C)
• Influenza
• Herpes viruses
• COVID-19 and emerging viral infections
• Others (respiratory syncytial virus, cytomegalovirus, etc.)
By Distribution Channel:
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By End-User:
• Hospitals & clinics
• Specialty treatment centers
• Home healthcare settings
Summary:
The segmentation illustrates the market's diverse scope, with HIV/AIDS and hepatitis dominating demand, while COVID-19 and pandemic preparedness continue to influence growth trajectories. Polymerase and protease inhibitors remain core drug classes, but newer therapies such as monoclonal antibodies and host-directed antivirals are gaining traction.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72617/antiviral-drugs-market
Regional Analysis
North America
• Largest market, driven by advanced healthcare systems, high disease burden (notably HIV and hepatitis), and strong pharmaceutical R&D infrastructure.
• U.S. accounts for a major share due to ongoing government initiatives for pandemic preparedness.
Europe
• Significant share supported by universal healthcare access, favorable drug reimbursement policies, and strong biotech research presence.
• Key markets include Germany, France, and the UK.
Asia-Pacific
• Fastest-growing region, with expanding healthcare access in China, India, and Southeast Asia.
• Rising cases of hepatitis and government-backed immunization programs are boosting demand.
Middle East & Africa
• Steady growth with rising prevalence of viral infections and limited vaccine coverage.
• Increased focus on improving healthcare infrastructure in Gulf nations.
Latin America
• Brazil and Mexico are key contributors, supported by growing awareness and expanding treatment access programs.
Summary:
While North America and Europe dominate in revenue, Asia-Pacific is projected to record the fastest CAGR (~6%) due to rising healthcare expenditure, increasing awareness of viral diseases, and expansion of pharmaceutical manufacturing capacity.
Market Dynamics
Key Growth Drivers:
• Rising global burden of chronic viral diseases (HIV, hepatitis).
• Increased demand for pandemic preparedness and stockpiling antiviral drugs.
• Technological advancements in drug design and molecular virology.
• Growing investment in host-targeted therapies and biologics.
Key Challenges:
• Emergence of drug-resistant viral strains limiting long-term efficacy.
• High costs of R&D and stringent regulatory approvals.
• Limited access to antivirals in low- and middle-income countries.
Latest Trends:
• Growing use of combination therapies to counter resistance.
• Integration of AI in drug discovery for faster development.
• Expansion of oral, long-acting, and injectable formulations.
• Increasing focus on broad-spectrum antivirals to prepare for future pandemics.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72617
Competitor Analysis
Major Players in the Antiviral Drugs Market:
• Gilead Sciences - Leader in HIV and hepatitis C antivirals (Truvada, Veklury).
• GlaxoSmithKline (GSK) - Strong portfolio in HIV therapies via its ViiV Healthcare division.
• Merck & Co. - Focused on hepatitis C and HIV antivirals.
• Roche - Known for influenza treatments such as Tamiflu.
• Bristol-Myers Squibb - Active in HIV and hepatitis drug development.
• AbbVie - Leading in combination therapies for hepatitis C.
• Johnson & Johnson - Expanding HIV and COVID-19 drug portfolios.
• Cipla - Providing cost-effective generic antivirals for global markets.
Competitive Summary:
The market is moderately consolidated, with global pharma giants dominating revenues through patent-protected blockbuster drugs. However, the rise of generic manufacturers in Asia is intensifying competition, especially in cost-sensitive markets. Future dynamics will revolve around innovation in resistance-proof drugs, biologics, and accessible generics.
Conclusion
The Antiviral Drugs Market is entering a new era of strategic innovation, balancing the need for broad-spectrum therapies with targeted solutions for chronic viral infections. With a projected value of USD 97.5 billion by 2034, the sector represents both a critical healthcare necessity and a substantial business opportunity.
Key Takeaways:
• Market to grow at 4.8% CAGR (2024-2034).
• HIV/AIDS and hepatitis remain leading applications, with influenza and COVID-19 shaping ongoing demand.
• North America leads in adoption, but Asia-Pacific will experience the fastest growth.
• Industry competition is driven by innovation, pandemic preparedness, and generic expansion.
• Opportunities lie in AI-driven drug discovery, combination therapies, and biologics.
In an era defined by viral threats, the antiviral drugs market is set to play a pivotal role in global health security, ensuring both innovation and accessibility in the fight against viral diseases.
This report is also available in the following languages : Japanese (抗ウイルス薬市場), Korean (항바이러스제 시장), Chinese (抗病毒药物市场), French (Marché des médicaments antiviraux), German (Markt für antivirale Medikamente), and Italian (Mercato dei farmaci antivirali), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72617/antiviral-drugs-market#request-a-sample
Our More Reports:
Clinical Trial Software Market
https://exactitudeconsultancy.com/reports/73711/clinical-trial-software-market
Precision Medicine Software Market
https://exactitudeconsultancy.com/reports/73712/precision-medicine-software-market
Pharma Cloud Services Market
https://exactitudeconsultancy.com/reports/73713/pharma-cloud-services-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Two potent novel antiviral drugs for SARS-CoV-2 here
News-ID: 4202332 • Views: …
More Releases from Exactitude Consultancy
SSG Hospital launches an AI-powered oncology chatbot
The global AI in Oncology Market is rapidly emerging as one of the most transformative frontiers in healthcare, combining advanced machine learning, big data analytics, and clinical expertise to fight cancer. With oncology representing one of the most complex medical domains, artificial intelligence (AI) is reshaping how clinicians detect, diagnose, and treat cancer. AI is accelerating drug discovery, enhancing diagnostic imaging, enabling personalized treatment recommendations, and improving patient monitoring. As…
Orion and Abilita Therapeutics Announce Research Partnership to Create Next-Gene …
The global Next-Generation Antibody Therapeutics Market is experiencing rapid growth as pharmaceutical and biotechnology companies push the boundaries of antibody engineering to deliver safer, more effective, and highly targeted therapies. Unlike conventional monoclonal antibodies, next-generation formats-such as bispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments, and engineered scaffolds-offer enhanced specificity, improved pharmacokinetics, and novel mechanisms of action. These innovations are revolutionizing treatment landscapes in oncology, autoimmune disorders, infectious diseases, and rare…
Prospects for the NAMPT Inhibitors Market in 2025-2034 | Pfizer Inc., Novartis A …
The NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitor Market is gaining momentum as researchers and biopharmaceutical companies explore novel therapeutic strategies targeting cellular metabolism and inflammatory pathways. NAMPT, a key enzyme in the NAD+ biosynthesis pathway, has been implicated in cancer cell survival, immune regulation, and metabolic disorders. Inhibitors of NAMPT have emerged as promising candidates for oncology, autoimmune conditions, and age-related diseases. With clinical trials expanding and increasing R&D investments, the NAMPT…
Acute lymphoblastic leukemia: a comprehensive review and 2025 latest update
Introduction
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow that primarily affects white blood cell precursors. While relatively rare compared to other cancers, it is the most common type of cancer in children, though it also affects adults, where prognosis is often poorer.
The management of ALL has improved significantly in recent decades due to advances in chemotherapy regimens, targeted therapies, and immunotherapies such as CAR-T…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
